AAPL315.91-4.06 (-1.27%) ▼|ABBV250.62-5.84 (-2.28%) ▼|ABT105.97-2.37 (-2.18%) ▼|ACN177.76-8.96 (-4.80%) ▼|ADBE257.30-9.22 (-3.46%) ▼|AMAT470.11+15.40 (+3.39%) ▲|AMD510.97+33.40 (+6.99%) ▲|AMGN397.35-39.88 (-9.12%) ▼|AMT177.08+1.23 (+0.70%) ▲|AMZN257.01-1.50 (-0.58%) ▼|AVGO367.18+9.29 (+2.59%) ▲|AXP326.95+0.79 (+0.24%) ▲|BA211.52-0.73 (-0.34%) ▼|BAC62.70+0.02 (+0.02%) ▲|BKNG180.60-12.69 (-6.57%) ▼|BLK1,104.39-12.18 (-1.09%) ▼|BMY65.06-1.76 (-2.63%) ▼|BNY164.00-0.84 (-0.51%) ▼|BRK-B504.46-1.58 (-0.31%) ▼|C137.58-0.15 (-0.11%) ▼|CAT826.91+12.97 (+1.59%) ▲|CL88.60-0.17 (-0.19%) ▼|CMCSA26.08-0.41 (-1.55%) ▼|COF215.20-4.40 (-2.00%) ▼|COP134.37+0.11 (+0.08%) ▲|COST909.62-6.13 (-0.67%) ▼|CRM248.81-10.43 (-4.02%) ▼|CSCO109.08-0.12 (-0.11%) ▼|CVS96.49-0.25 (-0.26%) ▼|CVX209.56+0.96 (+0.46%) ▲|DE683.49-10.05 (-1.45%) ▼|DHR206.03-1.63 (-0.78%) ▼|DIS104.56-0.76 (-0.72%) ▼|DUK121.26+1.04 (+0.86%) ▲|EMR152.12-0.70 (-0.46%) ▼|FDX316.67-5.85 (-1.81%) ▼|GD356.85-2.54 (-0.71%) ▼|GE337.88+0.76 (+0.23%) ▲|GEV970.68+28.73 (+3.05%) ▲|GILD146.62-4.38 (-2.90%) ▼|GM86.01-1.76 (-2.00%) ▼|GOOG336.36+1.05 (+0.31%) ▲|GOOGL339.57+1.11 (+0.33%) ▲|GS1,036.86-1.75 (-0.17%) ▼|HD315.43-5.63 (-1.75%) ▼|HON208.35-1.27 (-0.60%) ▼|IBM232.28-2.62 (-1.11%) ▼|INTC105.74+9.94 (+10.38%) ▲|INTU313.48-19.22 (-5.78%) ▼|ISRG351.24-15.46 (-4.22%) ▼|JNJ269.14-6.09 (-2.21%) ▼|JPM355.16-3.49 (-0.97%) ▼|KO88.36+0.29 (+0.32%) ▲|LIN468.57-9.00 (-1.88%) ▼|LLY1,126.65-22.71 (-1.98%) ▼|LMT538.18+12.90 (+2.46%) ▲|LOW201.70-2.76 (-1.35%) ▼|LRCX320.04+12.39 (+4.03%) ▲|MA567.69-11.52 (-1.99%) ▼|MCD255.75+0.06 (+0.02%) ▲|MDLZ61.43+0.15 (+0.24%) ▲|MDT92.59-1.58 (-1.68%) ▼|META617.95+1.18 (+0.19%) ▲|MMM166.52-2.04 (-1.21%) ▼|MO68.04-0.84 (-1.22%) ▼|MRK148.81-1.52 (-1.01%) ▼|MS217.85+0.13 (+0.06%) ▲|MSFT492.30-7.41 (-1.48%) ▼|MU1,018.61+2.02 (+0.20%) ▲|NEE84.04+0.61 (+0.73%) ▲|NFLX76.72-1.53 (-1.96%) ▼|NKE38.17-0.23 (-0.60%) ▼|NOW133.81-7.46 (-5.28%) ▼|NVDA225.90-4.47 (-1.94%) ▼|ORCL162.52+3.74 (+2.35%) ▲|PEP138.27+0.64 (+0.47%) ▲|PFE27.94-0.52 (-1.81%) ▼|PG145.34-1.10 (-0.75%) ▼|PLTR171.94-2.39 (-1.37%) ▼|PM185.54+3.01 (+1.65%) ▲|QCOM174.78+6.04 (+3.58%) ▲|RTX199.49-1.30 (-0.65%) ▼|SBUX102.27-2.20 (-2.11%) ▼|SCHW108.52-0.78 (-0.71%) ▼|SO88.89+0.78 (+0.89%) ▲|SPG211.61+2.17 (+1.04%) ▲|T25.50-0.18 (-0.70%) ▼|TMO605.92-7.86 (-1.28%) ▼|TMUS179.68-1.84 (-1.01%) ▼|TSLA367.79+13.71 (+3.87%) ▲|TXN257.14-1.30 (-0.50%) ▼|UBER73.24-2.52 (-3.33%) ▼|UNH403.34+6.20 (+1.56%) ▲|UNP290.17+0.55 (+0.19%) ▲|UPS100.82-1.48 (-1.44%) ▼|USB62.83-0.55 (-0.86%) ▼|V368.69-6.38 (-1.70%) ▼|VZ50.13-0.02 (-0.03%) ▼|WFC88.83-1.14 (-1.27%) ▼|WMT106.07-1.08 (-1.00%) ▼|XOM159.49+0.02 (+0.01%) ▲|AAPL315.91-4.06 (-1.27%) ▼|ABBV250.62-5.84 (-2.28%) ▼|ABT105.97-2.37 (-2.18%) ▼|ACN177.76-8.96 (-4.80%) ▼|ADBE257.30-9.22 (-3.46%) ▼|AMAT470.11+15.40 (+3.39%) ▲|AMD510.97+33.40 (+6.99%) ▲|AMGN397.35-39.88 (-9.12%) ▼|AMT177.08+1.23 (+0.70%) ▲|AMZN257.01-1.50 (-0.58%) ▼|AVGO367.18+9.29 (+2.59%) ▲|AXP326.95+0.79 (+0.24%) ▲|BA211.52-0.73 (-0.34%) ▼|BAC62.70+0.02 (+0.02%) ▲|BKNG180.60-12.69 (-6.57%) ▼|BLK1,104.39-12.18 (-1.09%) ▼|BMY65.06-1.76 (-2.63%) ▼|BNY164.00-0.84 (-0.51%) ▼|BRK-B504.46-1.58 (-0.31%) ▼|C137.58-0.15 (-0.11%) ▼|CAT826.91+12.97 (+1.59%) ▲|CL88.60-0.17 (-0.19%) ▼|CMCSA26.08-0.41 (-1.55%) ▼|COF215.20-4.40 (-2.00%) ▼|COP134.37+0.11 (+0.08%) ▲|COST909.62-6.13 (-0.67%) ▼|CRM248.81-10.43 (-4.02%) ▼|CSCO109.08-0.12 (-0.11%) ▼|CVS96.49-0.25 (-0.26%) ▼|CVX209.56+0.96 (+0.46%) ▲|DE683.49-10.05 (-1.45%) ▼|DHR206.03-1.63 (-0.78%) ▼|DIS104.56-0.76 (-0.72%) ▼|DUK121.26+1.04 (+0.86%) ▲|EMR152.12-0.70 (-0.46%) ▼|FDX316.67-5.85 (-1.81%) ▼|GD356.85-2.54 (-0.71%) ▼|GE337.88+0.76 (+0.23%) ▲|GEV970.68+28.73 (+3.05%) ▲|GILD146.62-4.38 (-2.90%) ▼|GM86.01-1.76 (-2.00%) ▼|GOOG336.36+1.05 (+0.31%) ▲|GOOGL339.57+1.11 (+0.33%) ▲|GS1,036.86-1.75 (-0.17%) ▼|HD315.43-5.63 (-1.75%) ▼|HON208.35-1.27 (-0.60%) ▼|IBM232.28-2.62 (-1.11%) ▼|INTC105.74+9.94 (+10.38%) ▲|INTU313.48-19.22 (-5.78%) ▼|ISRG351.24-15.46 (-4.22%) ▼|JNJ269.14-6.09 (-2.21%) ▼|JPM355.16-3.49 (-0.97%) ▼|KO88.36+0.29 (+0.32%) ▲|LIN468.57-9.00 (-1.88%) ▼|LLY1,126.65-22.71 (-1.98%) ▼|LMT538.18+12.90 (+2.46%) ▲|LOW201.70-2.76 (-1.35%) ▼|LRCX320.04+12.39 (+4.03%) ▲|MA567.69-11.52 (-1.99%) ▼|MCD255.75+0.06 (+0.02%) ▲|MDLZ61.43+0.15 (+0.24%) ▲|MDT92.59-1.58 (-1.68%) ▼|META617.95+1.18 (+0.19%) ▲|MMM166.52-2.04 (-1.21%) ▼|MO68.04-0.84 (-1.22%) ▼|MRK148.81-1.52 (-1.01%) ▼|MS217.85+0.13 (+0.06%) ▲|MSFT492.30-7.41 (-1.48%) ▼|MU1,018.61+2.02 (+0.20%) ▲|NEE84.04+0.61 (+0.73%) ▲|NFLX76.72-1.53 (-1.96%) ▼|NKE38.17-0.23 (-0.60%) ▼|NOW133.81-7.46 (-5.28%) ▼|NVDA225.90-4.47 (-1.94%) ▼|ORCL162.52+3.74 (+2.35%) ▲|PEP138.27+0.64 (+0.47%) ▲|PFE27.94-0.52 (-1.81%) ▼|PG145.34-1.10 (-0.75%) ▼|PLTR171.94-2.39 (-1.37%) ▼|PM185.54+3.01 (+1.65%) ▲|QCOM174.78+6.04 (+3.58%) ▲|RTX199.49-1.30 (-0.65%) ▼|SBUX102.27-2.20 (-2.11%) ▼|SCHW108.52-0.78 (-0.71%) ▼|SO88.89+0.78 (+0.89%) ▲|SPG211.61+2.17 (+1.04%) ▲|T25.50-0.18 (-0.70%) ▼|TMO605.92-7.86 (-1.28%) ▼|TMUS179.68-1.84 (-1.01%) ▼|TSLA367.79+13.71 (+3.87%) ▲|TXN257.14-1.30 (-0.50%) ▼|UBER73.24-2.52 (-3.33%) ▼|UNH403.34+6.20 (+1.56%) ▲|UNP290.17+0.55 (+0.19%) ▲|UPS100.82-1.48 (-1.44%) ▼|USB62.83-0.55 (-0.86%) ▼|V368.69-6.38 (-1.70%) ▼|VZ50.13-0.02 (-0.03%) ▼|WFC88.83-1.14 (-1.27%) ▼|WMT106.07-1.08 (-1.00%) ▼|XOM159.49+0.02 (+0.01%) ▲|
25.3 C
New York
Tuesday, September 8, 2026

Tag: body

The Pink Salt Trick Recipe for Fast Weight Loss Trend in 2025: Why ProZenith Is the Science-Backed Alternative

Why the TikTok Pink Salt Trick Went Viral in 2025 —and How ProZenith Offers a Science‑Based Solution for Hormonal Metabolic Support
Why the TikTok Pink Salt Trick Went Viral in 2025 —and How ProZenith Offers a Science‑Based Solution for Hormonal Metabolic Support

InventHelp Inventors Develop New Decoy for Waterfowl Hunters (RKH-796)

PITTSBURGH, July 28, 2025 /PRNewswire/ -- "We thought there could be a better way to extend and retract the tether on a waterfowl decoy when...

InventHelp Inventor Develops New Bathroom Towel Set (RKH-790)

PITTSBURGH, July 28, 2025 /PRNewswire/ -- "I wanted to create a new bathroom towel set that would allow for specific cleaning and drying of...

Napino Tech Ventures and Teksun Launch Rapidise with $4M Seed Funding to Accelerate AIoT Product Innovation and Electronics Manufacturing

SAN FRANCISCO and NEW DELHI, July 28, 2025 /PRNewswire/ -- Napino Tech Ventures Pvt. Ltd. (NTV) and Teksun Microsys Pvt. Ltd. have launched Rapidise Technology...

Napino Tech Ventures and Teksun Launch Rapidise with $4M Seed Funding to Accelerate AIoT Product Innovation and Electronics Manufacturing

SAN FRANCISCO and NEW DELHI, July 28, 2025 /CNW/ -- Napino Tech Ventures Pvt. Ltd. (NTV) and Teksun Microsys Pvt. Ltd. have launched Rapidise Technology...

Elevate Holistics Launches Comprehensive Cannabis E-Book After Years of Consulting Patients on the Most Important Questions When It Comes to Cannabis

MORGANTOWN, W.Va., July 28, 2025 /PRNewswire/ -- "Everything You've Ever Wanted to Know About Cannabis, Finally Written Down" ...

BATMAN brings TCR therapy out of the shadows

COLD SPRING HARBOR, N.Y., July 28, 2025 /PRNewswire/ -- Imagine your immune cells could be modified to attack any kind of cancer. T cell...

NEW GOLD REPORTS SECOND QUARTER 2025 RESULTS

Quarter-Over-Quarter Production Growth Drives Record Free Cash Flow Generation; On-Track to Achieve Annual Guidance (All amounts are in U.S. dollars unless otherwise indicated) TORONTO, July 28,...

NEW GOLD REPORTS SECOND QUARTER 2025 RESULTS

Quarter-Over-Quarter Production Growth Drives Record Free Cash Flow Generation; On-Track to Achieve Annual Guidance (All amounts are in U.S. dollars unless otherwise indicated) TORONTO, July 28,...

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC). NPC is an ultra-rare, neurological disease caused by genetic mutations that result in lipid accumulation in cells, leading to visceral, neurological, and psychiatric symptoms. Arimoclomol is the only treatment shown to directly target the underlying pathology of NPC by increasing gene expression for improved lipid clearance. Arimoclomol for the treatment of NPC has been designated as an Orphan Medicinal Product by the EMA. Arimoclomol is marketed in the U.S. under the brand name MIPLYFFA®.

SOUEAST Unveils New Chapter in Egypt, Strengthening African Market Presence

Cairo, July 24th, 2025—SOUEAST launched four new models in Egypt, marking a significant expansion in the African market.

Best Kratom? Super Speciosa Relaunches Enhanced Watermelon Kratom Tincture in 2025

As Consumer Demand Surges for Lab-Tested Botanical Products, Super Speciosa Responds With a Timely Tincture Update and GMP-Backed Transparency
As Consumer Demand Surges for Lab-Tested Botanical Products, Super Speciosa Responds With a Timely Tincture Update and GMP-Backed Transparency

POP BIO and CEPI announce collaboration for faster responses to Disease X

Buffalo, NY, July 25, 2025 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a biotechnology company specializing in nanoparticle-based vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a new collaboration to accelerate the development of vaccines against future pandemic threats, including a potential ‘Disease X’. Backed by up to $1.5 million in funding from CEPI, the partnership will advance POP BIO’s SNAP™ (Spontaneous Nanoliposome Antigen Particleization) platform—a plug-and-play technology designed to enable rapid-response vaccine development through streamlined protein purification and nanoparticle delivery.

Menovelle ‘Coffee Hack’ Fixes Hot Flashes, Belly Weight Gain & Mood Swings, Research Suggests

A Natural Supplement Trend in 2025, Menovelle Helps Women Support Hormonal Balance and Metabolic Energy Without Hormone Therapy or Stimulants
A Natural Supplement Trend in 2025, Menovelle Helps Women Support Hormonal Balance and Metabolic Energy Without Hormone Therapy or Stimulants

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBody